Clinical trial Recruiting at 1 site Observational Ages 18 and up

Volta AI software in real-world AF ablation

Official title: Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies

Run by Volta Medical · NCT07621055 · Data updated 2026-11-12

A real-world observational study will test the latest Volta AF-Xplorer II AI software during atrial fibrillation ablation to see how safe and effective it is over 24 months.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment150 (estimated)
SponsorVolta Medical
Industry-sponsored
Locations3 sites (Marseille and 2 other locations)
StatusRecruiting
StartedJune 16, 2026
Main results expectedJune 2030
Study endsJune 2030
Registry record updatedJune 22, 2026
Trial IDNCT07621055 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18+ with paroxysmal or persistent AF or related tachycardias eligible for catheter ablation and where Volta AF-Xplorer II is considered for use, in France.

Probably not a fit

Patients for whom the operator does not use Volta AF-Xplorer II or who have contraindications to the ablation approach may not experience any benefit from the AI software.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This PMCF study observes acute and long-term safety and performance of Volta AF-Xplorer II during AF ablation in routine clinical practice. It uses next-generation mapping and ablation tools, with the ablation approach chosen by the operator. Participants are followed through standard care visits at 3, 6, 9 and 24 months, collecting adverse events, arrhythmia recurrences, heart failure symptoms, AF-related symptoms, and a general health quality-of-life measure. The study records outcomes from enrollment to 24 months post-ablation, without imposing new workflows.

Why it matters

Potential benefit: If successful, patients may experience improved ablation guidance and potentially better safety and effectiveness through the AI software.

How similar studies have gone: Previous studies using similar AI-guided mapping tools have shown promise, but this specific real-world PMCF with Volta AF-Xplorer II is still exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient aged 18 years or older.
2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II.
3. Patient able and willing to provide written informed consent to participate in the study.
4. Only for France: Patient affiliated to the French social security system.

Exclusion Criteria:

1. Contraindication to AF/AT catheter ablation using RF and/or PFA.
2. Patient who is or could potentially be pregnant.
3. Person deprived of liberty or under guardianship.
4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons.
5. Patient's refusal to participate in the study.
6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.

Where it's running

  • Hôpital Saint-Joseph Marseille
    Marseille, France
    Recruiting
  • Centre Cardiologique du Nord
    Saint-Denis, France
    Not yet recruiting
  • Clinique Rhéna
    Strasbourg, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.